Encouraging Safety & Efficacy with for Mono/Combo TG-1701 Therapy
TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...
Read More